• Antithrombotic Trialists' Collaboration (2002). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 7186.
  • Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Torunier B et al. (2001). Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345: 18091817.
  • Curtis JP, Wang Y, Portnay EL, Masoudi FA, Havranek EP, Krumholz HM (2003). Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. BMJ 327: 13221323.
  • Farkouh ME, Greenberg JD, Jeger RV, Ramanathan K, Verheugt FW, Chesebro JH et al. (2007). Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis 66: 764770.
  • Gengo FM, Robson M, Rainka M, Gengo FM, Mager DE, Bates V (2008). Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. J Clin Pharmacol 48: 117122.
  • Gladding PA, Webster MWI, Farrell HB, Zeng ISL, Park R, Ruijne N (2008). The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 101: 10601063.
  • Hovestad-Witterland AHI, Klein Gunnewiek JMT, De Metz M, Vollaard EJ (2003). COX-2-preferentiele NSAID's nader aan de tand gevoeld. Pharm Weekbl 138: 104107.
  • Klein Gunnewiek JMT, Hovestad-Witterland AHI, Vollaard EJ, Fleuren HWHA, De Metz M (2005). The influence of acetylsalicylic acid intake by healthy volunteers on duplicate PFA-100 measurements. Blood Coagul Fibrinolysis 16: 337340.
  • Kurth T, Glynn RJ, Walker AM, Chan KA, Buring JE, Hennekens CH et al. (2003). Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal anti-inflammatory drugs. Circulation 108: 11911195.
  • Loll PJ, Picot D, Garavito RM (1995). The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 2: 637643.
  • MacDonald TMF, Wei L (2003). Effect of ibuprofen on cardioprotective effect of aspirin. The Lancet 361: 573774.
  • Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F et al. (1985). Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72: 11771184.
  • Patrono C, Coller B, Dalen JE, FitzGerald GA, Fusters V, Gent M et al. (2001). Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 119: 39S63S.
  • Pradelles P, Grassi J, Maclouf J (1985). Enzyme immunoassays of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay. Anal Chem 57: 11701173.
  • Renda G, Tacconelli S, Capone ML, Sacchtetta D, Santarelli F, Sciulli M et al. (2006). Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther 80: 264274.
  • The Dutch TIA Trial Study Group (1991). A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. N Engl J Med 325: 12611266.
  • Van Hecken A, Schwartz JI, Depré M, De Lepeleire I, Dallob A, Tanaka W et al. (2000). Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 40: 11091120.
  • Van Kraaij DJ, Hovestad-Witterland AHI, De Metz M, Vollaard EJ (2002). A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers. Br J Clin Pharmacol 53: 644647.